Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1801 to 1815 of 9128 results

  1. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]

    Awaiting development Reference number: GID-TA11489 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development Reference number: GID-TA11517 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Advanced breast cancer: diagnosis and management (Partial update)

    In development Reference number: GID-NG10430 Expected publication date: TBC

    NICE guideline
    In development

  4. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia [TSID12043]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. MMprofiler for prognostic risk classification in multiple myeloma (MT623) (MIB270)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  6. High intensity focused ultrasound ablation for pain caused by bone metastases

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  7. Transarterial radio embolisation for osteosarcoma liver metastases

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  8. Subcutaneous isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [TSID11969]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia [TSID12043]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. CT-P39 (omalizumab biosimilar) for previously treated chronic spontaneous urticaria [TSID11832]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults [ID1297]

    Technology appraisal Reference number: TA714 Published:  14 July 2021

    Technology appraisal guidance
    In development

  12. Helge for detecting haemolysis

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  13. Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable [ID6272]

    Topic prioritisation

    Topic prioritisation

  14. Spectra Optia for plasma exchange, (MT828)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  15. Zanubrutinib for Chronic lymphocytic leukaemia (CLL) or Follicular lymphoma or Marginal zone lymphoma (MZL) or Waldenstrom's macroglobulinaemia [ID12199]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation